Adjunct tele-yoga on clinical status at 14 days in hospitalized patients with mild and moderate COVID-19: A randomized control trial

被引:1
|
作者
Majumdar, Vijaya [1 ]
Manjunath, N. K. [1 ]
Nagarathna, Raghuram [1 ]
Panigrahi, Suryanarayan [1 ]
Kanchi, Muralidhar [2 ]
Sahoo, Sarthak [2 ]
Nagendra, Hongasandra R. [1 ]
Giridharan, Adithi [1 ]
Reddy, Mounika [1 ]
Nayak, Rakshitha [1 ]
机构
[1] Swami Vivekananda Yoga Anusandhana Samsthana, Bengaluru, India
[2] Narayana Hlth City, Bengaluru, India
关键词
tele-yoga; COVID-19; hospitalized patients; clinical status; India;
D O I
10.3389/fpubh.2023.1054207
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The initial insights from the studies on COVID-19 had been disappointing, indicating the necessity of an aggravated search for alternative strategies. In this regard, the adjunct potential of yoga has been proposed for enhancing the effectiveness of the standard of care with respect to COVID-19 management. We tested whether a telemodel of yoga intervention could aid in better clinical management for hospitalized patients with mild-to-moderate COVID-19 when complemented with the standard of care. Methods: This was a randomized controlled trial conducted at the Narayana Hrudyalaya, Bengaluru, India, on hospitalized patients with mild-to-moderate COVID-19 infection enrolled between 31 May and 22 July 2021. The patients (n = 225) were randomized in a 1:1 ratio [adjunct tele-yoga (n = 113) or standard of care]. The adjunct yoga group received intervention in tele-mode within 4-h post-randomization until 14 days along with the standard of care. The primary outcome was the clinical status on day 14 post-randomization, assessed with a seven-category ordinal scale. The secondary outcome set included scores on the COVID Outcomes Scale on day 7, follow-up for clinical status and all-cause mortality on day 28, post-randomization, duration of days at the hospital, 5th-day changes post-randomization for viral load expressed as cyclic threshold (Ct), and inflammatory markers and perceived stress scores on day 14. Results: As compared with the standard of care alone, the proportional odds of having a higher score on the 7-point ordinal scale on day 14 were similar to 1.8 for the adjunct tele-yoga group (OR = 1.83, 95% CI, 1.11-3.03). On day 5, there were significant reductions in CRP (P = 0.001) and LDH levels (P = 0.029) in the adjunct yoga group compared to the standard of care alone. CRP reduction was also observed as a potential mediator for the yoga-induced improvement of clinical outcomes. The Kaplan-Meier estimate of all-cause mortality on day 28 was the adjusted hazard ratio (HR) of 0.26 (95% CI, 0.05-1.30). Conclusion: The observed 1.8-fold improvement in the clinical status on day 14 of patients of COVID-19 with adjunct use of tele-yoga contests its use as a complementary treatment in hospital settings.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19 A Randomized Clinical Trial
    Self, Wesley H.
    Semler, Matthew W.
    Leither, Lindsay M.
    Casey, Jonathan D.
    Angus, Derek C.
    Brower, Roy G.
    Chang, Steven Y.
    Collins, Sean P.
    Eppensteiner, John C.
    Filbin, Michael R.
    Files, D. Clark
    Gibbs, Kevin W.
    Ginde, Adit A.
    Gong, Michelle N.
    Harrell, Frank E.
    Hayden, Douglas L.
    Hough, Catherine L.
    Johnson, Nicholas J.
    Khan, Akram
    Lindsell, Christopher J.
    Matthay, Michael A.
    Moss, Marc
    Park, Pauline K.
    Rice, Todd W.
    Robinson, Bryce R. H.
    Schoenfeld, David A.
    Shapiro, Nathan, I
    Steingrub, Jay S.
    Ulysse, Christine A.
    Weissman, Alexandra
    Yealy, Donald M.
    Thompson, B. Taylor
    Brown, Samuel M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (21): : 2165 - 2176
  • [2] ANKYLOSING SPONDYLITIS AND TELE-YOGA DURING COVID-19 PANDEMIC: PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL
    Acar, Y.
    Ilcin, N.
    Sari, I.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1095 - 1095
  • [3] Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial
    Darazam, Ilad Alavi
    Shokouhi, Shervin
    Mardani, Masoud
    Pourhoseingholi, Mohamad Amin
    Rabiei, Mohammad Mahdi
    Hatami, Firouze
    Shabani, Minoosh
    Moradi, Omid
    Gharehbagh, Farid Javandoust
    Irvani, Seyed Sina Naghibi
    Amirdosara, Mahdi
    Hajiesmaeili, Mohammadreza
    Rezaei, Omidvar
    Khoshkar, Ali
    Lotfollahi, Legha
    Gachkar, Latif
    Dehbsneh, Hadiseh Shabanpour
    Khalili, Negar
    Soleymaninia, Azam
    Kusha, Akram Hoseyni
    Shoushtari, Maryam Taleb
    Torabinavid, Parham
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 99
  • [4] The Role of Yoga in Hospitalized COVID-19 Patients: An Exploratory Randomized Controlled Trial
    Dua, Ruchi
    Malik, Saloni
    Kumari, Ranjeeta
    Naithani, Manisha
    Panda, Prasan K.
    Saroha, Amit
    Omar, Balram
    Pathania, Monika
    Saxena, Sudhir
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)
  • [5] Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
    Spinner, Christoph D.
    Gottlieb, Robert L.
    Criner, Gerard J.
    Arribas Lopez, Jose Ramon
    Cattelan, Anna Maria
    Soriano Viladomiu, Alex
    Ogbuagu, Onyema
    Malhotra, Prashant
    Mullane, Kathleen M.
    Castagna, Antonella
    Chai, Louis Yi Ann
    Roestenberg, Meta
    Tsang, Owen Tak Yin
    Bernasconi, Enos
    Le Turnier, Paul
    Chang, Shan-Chwen
    SenGupta, Devi
    Hyland, Robert H.
    Osinusi, Anu O.
    Cao, Huyen
    Blair, Christiana
    Wang, Hongyuan
    Gaggar, Anuj
    Brainard, Diana M.
    McPhail, Mark J.
    Bhagani, Sanjay
    Ahn, Young
    Sanyal, Arun J.
    Huhn, Gregory
    Marty, Francisco M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (11): : 1048 - 1057
  • [6] An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients
    Ravichandran, Rajan
    Mohan, Surapaneni Krishna
    Sukumaran, Suresh Kumar
    Kamaraj, Devakumar
    Daivasuga, Sumetha Suga
    Ravi, Samson Oliver Abraham Samuel
    Vijayaraghavalu, Sivakumar
    Kumar, Ramarathnam Krishna
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [7] Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
    Niaee, Morteza Shakhsi
    Namdar, Peyman
    Allami, Abbas
    Zolghadr, Leila
    Javadi, Amir
    Karampour, Amin
    Varnaseri, Mehran
    Bijani, Behzad
    Cheraghi, Fatemeh
    Naderi, Yazdan
    Amini, Fatemeh
    Karamyan, Masoumeh
    YadYad, MohammadJafar
    Jamshidian, Ramin
    Gheibi, Nematollah
    [J]. ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2021, 14 (06) : 266 - 273
  • [8] Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
    Morteza Shakhsi Niaee
    Peyman Namdar
    Abbas Allami
    Leila Zolghadr
    Amir Javadi
    Amin Karampour
    Mehran Varnaseri
    Behzad Bijani
    Fatemeh Cheraghi
    Yazdan Naderi
    Fatemeh Amini
    Masoumeh Karamyan
    Mohammad Jafar YadYad
    Ramin Jamshidian
    Nematollah Gheibi
    [J]. Asian Pacific Journal of Tropical Medicine, 2021, 14 (06) : 266 - 273
  • [9] Role of ivermectin in hospitalized patients with mild to moderate COVID-19
    Zubair, Syed Muhammad
    Zahid, Aqusa
    Shahzad, Talha
    Zubairi, Ali Bin Sarwar
    Khan, Javaid Ahmed
    Irfan, Muhammad
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [10] Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19
    Lamback, Elisa Baranski
    de Oliveira, Monica Amorim
    Haddad, Andrea Ferreira
    Marcondes Vieira, Andre Filipe
    Ferreira Neto, Armando Leao
    Maia, Taciana da Silva
    Chrisman, Juliana de Rezende
    de Mello Spineti, Pedro Pimenta
    de Mattos, Marco Antonio
    Costa, Eduardo
    [J]. BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2021, 25 (02):